Zobrazeno 1 - 10
of 20
pro vyhledávání: '"33"'
Autor:
Etienne, De Braekeleer, Nathalie, Douet-Guilbert, Frédéric, Morel, Marie-Josée, Le Bris, Audrey, Basinko, Christian, Berthou, Patrick, Morice, Claude, Férec, Marc, De Braekeleer
Publikováno v:
Anticancer research. 30(2)
The Philadelphia (Ph) chromosome, resulting from a t(9;22)(q34;q11), is one of the most frequent chromosomal abnormalities observed among patients with acute lymphoblastic leukemia (ALL). Main of study: To analyze the distribution of Ph chromosome-po
Autor:
Takeshi Ishii, Yoko Hagiwara, Hideyuki Kinoshita, Hiroto Kamoda, Tsukasa Yonemoto, Fumihide Terakawa, Toshinori Tsukanishi, Masahiro Inoue, Seiji Ohtori
Publikováno v:
Anticancer Research. 41:1041-1046
Background/aim This study aimed to investigate the effectiveness of knee rotationplasty (KRP) as salvage surgery for uncontrolled infection and implant failure of total knee arthroplasty (TKA) for sarcoma around the knee in adolescents and young adul
Autor:
YUKARI BANDO, JUNYA FURUKAWA, YASUYOSHI OKAMURA, TAKUTO HARA, TOMOAKI TERAKAWA, YUZO NAKANO, MASATO FUJISAWA
Publikováno v:
Anticancer research. 42(2)
The survival benefit of immune checkpoint inhibitors for non-clear cell renal cell carcinoma (nccRCC) is unclear. Our purpose was to evaluate the real-world survival benefit of ipilimumab plus nivolumab retrospectively.We retrospectively reviewed med
Autor:
Yoshifumi, Nakayama, Tatsuhiko, Sako, Kazunori, Shibao, Keisuke, Okazaki, Nie, Rempo, Koji, Onitsuka, Noritaka, Minagawa, Kazuhisa, Akahane, Nobuo, Nagashima, Naoki, Nagata, Hideaki, Itoh
Publikováno v:
Anticancer research. 22(4)
Vascular endothelial growth factor (VEGF) is thought to be the most powerful angiogenic factor in many malignancies while and several reports have determined serum VEGF to be a prognostic indicator for various malignancies. However, serum VEGF may no
Autor:
Tomonori Hirashima, Fumio Imamura, Yoshihiko Taniguchi, Akihiro Tamiya, Kei Kunimasa, Hidekazu Suzuki, Toru Kumagai, Madoka Kimura, Motohiro Tamiya, Kenji Nakahama, Kazumi Nishino, Takako Inoue, Kazunori Moriizumi, Hanako Kuhara, Shinji Atagi
Publikováno v:
Anticancer Research. 39:3923-3929
Background/aim Treatment with EGFR-tyrosine kinase inhibitor (TKI) shows a durable response against NSCLC harboring EGFR mutation; however, treatment resistance occurs within 1-1.5 years following first-line EGFR-TKIs [first- and second-generation (G
Autor:
Giannis, Mountzios, Xanthippi, Mavropoulou, Georgia-Angeliki, Koliou, Helena, Linardou, Epaminontas, Samantas, Paris, Kosmidis, George, Fountzilas, Aphrodite, Charitandi, Anna, Kalogera-Fountzila
Publikováno v:
Anticancer research. 40(4)
The mechanism of action of bevacizumab and erlotinib is quite different in the treatment of advanced non-small cell lung cancer (NSCLC). This study sought to compare the two targeted therapies in terms of sequential tumor response metrics.Parameters
Autor:
Valentina Ciaravino, Luca Landoni, Paola Vallerio, Sara Cingarlini, Aldo Scarpa, Stefano Crosara, Elisabetta Grego, Silvia Ortolani, Riccardo De Robertis, Mirko D'Onofrio, Claudio Bassi, Andrea Ruzzenente, Giampaolo Tortora
Publikováno v:
Anticancer Research. 37:1305-1312
Aim To evaluate modifications of perfusional parameters assessed by perfusion computed tomography (P-CT) of liver metastases (LM) from pancreatic neuroendocrine tumors (PanNETs) during everolimus treatment. Patients and methods All patients with LMs
Autor:
Joji Sakurai, Ken-Ichi Arita, Souichi Kitaguchi, Isao Murakami, Kikuo Nakano, Masahiro Yamasaki, Mihoko Doi, Noboru Hattori, Tomohiro Kondo
Publikováno v:
Anticancer Research. 37:923-928
Aim We aimed to evaluate the efficacy and safety of carboplatin plus weekly paclitaxel with bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC). Patients and methods Patients with stage IIIB/IV or postoperative recur
Publikováno v:
Anticancer Research. 37
Background/aim Few studies have reported results with pulmonary metastasectomy for pancreatic ductal adenocarcinoma (PDAC), probably because of their extremely poor outcomes. The aim of this study was to review our institutional experience and analyz
Autor:
Tomoyuki Abe, Tomoyuki Minami, Shuji Yonehara, Hideki Ohdan, Keiji Hanada, Toshio Noriyuki, Hironobu Amano, Masahiro Nakahara, Minoru Hattori, Tsuyoshi Kobayashi, Toshikatsu Fukuda
Publikováno v:
Anticancer Research. 37
BACKGROUND/AIM Perioperative red blood cell transfusion (RBCT) can negatively affect the host's immune system. We investigated the effects of perioperative RBCT on long-term survival among patients with pancreatic ductal adenocarcinoma (PDAC). PATIEN